Trial Profile
A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Hyaluronidase (Primary) ; Linagliptin (Primary) ; Motixafortide (Primary) ; Tiragolumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin; Paclitaxel; Ramucirumab
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms MORPHEUS-GC
- Sponsors Roche
- 30 Jan 2024 Planned End Date changed from 8 Feb 2025 to 30 Apr 2025.
- 20 Jan 2024 Interim results (14 Mar 2023; n=152) assessing combination of tiragolumab plus atezolizumab with chemotherpay in patients untreated locally advanced unresectable or metastatic EC presented at the 2024 Gastrointestinal Cancers Symposium.
- 26 Oct 2023 Status changed from recruiting to active, no longer recruiting.